Blood · 2002 · 315 citations · 52 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunoregulationTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytokines In Tumor ImmunityGrowth Factor SignalingT Cell Responses To TumorsTumor Immune MicroenvironmentAdaptive Antitumor ImmunityTransforming Growth Factor Beta Receptor SignalingTransforming Growth Factor Beta ReceptorsTransforming Growth Factor Beta RegulationTransforming Growth Factor Beta Signaling ModulationTransforming Growth Factor Beta-mediated Immune SuppressionTransforming Growth Factor-beta Signaling
Transforming growth factor beta (TGF-beta), a pleiotropic cytokine that regulates cell growth and differentiation, is secreted by many human tumors and markedly inhibits tumor-specific cellular immunity. Tumors can avoid the differentiating and apoptotic effects of TGF-beta by expressing a nonfunctional TGF-beta receptor. We have determined whether this immune evasion strategy can be manipulated to shield tumor-specific cytotoxic T lymphocytes (CTLs) from the inhibitory effects of tumor-derived TGF-beta. As our model we used Epstein-Barr virus (EBV)-specific CTLs that are infused as treatment for EBV-positive Hodgkin disease but that are vulnerable to the TGF-beta produced by this tumor. CTLs were transduced with a retrovirus vector expressing the dominant-negative TGF-beta type II receptor HATGF-betaRII-Deltacyt. HATGF-betaRII-Deltacyt- but not green fluorescence protein (eGFP)-transduced CTLs was resistant to the antiproliferative and anticytotoxic effects of exogenous TGF-beta. Additionally, receptor-transduced cells continued to secrete cytokines in response to antigenic stimulation. TGF-beta receptor ligation results in phosphorylation of Smad2, and this pathway was disrupted in HATGF-betaRII-Deltacyt-transduced CTLs, confirming blockade of the signal transduction pathway. Long-term expression of TGF-betaRII-Deltacyt did not affect CTL function, phenotype, or growth characteristics. Tumor-specific CTLs expressing HATGF-betaRII-Deltacyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-beta-secreting tumors and may be of value in treatment of these diseases.
52
Anita B. Roberts, Michael B. Sporn, Richard K. Assoian et al. · Proceedings of the National Academy of Sciences · 1986 · 2.9K citations · Full text
Melinda Fitzgerald, Ian P. Hayward, Anita C. Thomas et al. · 1995 · 2.6K citations
Mechanism of activation of the TGF-β receptor
Jeffrey L. Wrana, Liliana Attisano, Rotraud Wieser et al. · Nature · 1994 · 2.3K citations
Transforming growth factor beta
Anita B. Roberts, Michael B. Sporn · SpringerReference · 2011 · 1.9K citations
Medicine, Ophthalmology, Surgery +16